Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 20/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.57 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ABCB4 | P21439 | 1/20 | 0.56 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.56 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.56 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.56 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17215397 | 1.00 | LPAR1 (0.57) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17215333 | 0.94 | LPAR1 (0.59) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17215335 | 0.94 | LPAR1 (0.59) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17367405 | 0.94 | LPAR1 (0.49) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL28888358 | 0.92 | LPAR1 (0.56) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17215438 | 0.92 | LPAR1 (0.51) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17215439 | 0.92 | LPAR1 (0.51) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17215416 | 0.90 | LPAR1 (0.49) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17215413 | 0.90 | LPAR1 (0.49) | LPAR1LPAR3ABCC3ABCC4ABCB11 | |
| SCHEMBL17215888 | 0.90 | LPAR1 (0.61) | LPAR1LPAR3ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3360869-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND USEFUL FOR THE TREATMENT OF DISEASES CAUSED BY LPA. | UBE INDUSTRIES (JP) | 2020-07-29 | — | — | EP | claimed |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2018-06-19 | — | — | US | claimed |
| EP-2940013-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES (JP) | 2018-02-21 | — | — | EP | claimed |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | claimed |
| EP-2940013-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE Industries, Ltd. (JP) | 2015-11-04 | — | — | EP | claimed |
| EP-3360869-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND USEFUL FOR THE TREATMENT OF DISEASES CAUSED BY LPA. | UBE INDUSTRIES (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| EP-2940013-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES (JP) | 2018-02-21 | — | — | EP | disclosed |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2940013-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE Industries, Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885ABCC3 607/4885 |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | LPAR1, LPAR4, LPAR2 | LPAR1 1/4885LPAR3 4/4885ABCC3 1823/4885 |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885ABCC3 607/4885 |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | LPAR3, LPAR1, LPAR2 | LPAR1 2/4885LPAR3 1/4885ABCC3 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.